FY2026 Earnings Forecast for Evolus Issued By HC Wainwright

Evolus, Inc. (NASDAQ:EOLS) – Analysts at HC Wainwright reduced their FY2026 EPS estimates for shares of Evolus in a research note issued to investors on Monday, March 30th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.22) per share for the year, down from their previous forecast of ($0.17). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus’ FY2027 earnings at $0.19 EPS, FY2028 earnings at $0.64 EPS, FY2029 earnings at $1.04 EPS and FY2030 earnings at $1.41 EPS.

Evolus (NASDAQ:EOLS) last posted its earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million for the quarter, compared to analysts’ expectations of $89.58 million.

EOLS has been the subject of several other reports. Wall Street Zen downgraded Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Mizuho set a $15.00 target price on shares of Evolus in a research report on Wednesday, February 4th. Finally, BTIG Research reissued a “buy” rating and set a $13.00 target price on shares of Evolus in a report on Wednesday, March 4th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Evolus currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Evolus Stock Up 4.3%

NASDAQ EOLS opened at $4.11 on Wednesday. The company has a market cap of $267.40 million, a price-to-earnings ratio of -5.07 and a beta of 1.02. Evolus has a twelve month low of $3.86 and a twelve month high of $12.51. The business’s fifty day moving average is $4.65 and its 200 day moving average is $5.88.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue bought a new stake in shares of Evolus in the 3rd quarter valued at $26,000. Larson Financial Group LLC raised its stake in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after buying an additional 2,837 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Evolus during the fourth quarter worth $34,000. Wexford Capital LP acquired a new position in Evolus in the third quarter valued at $37,000. Finally, Aquatic Capital Management LLC bought a new stake in Evolus during the third quarter valued at $48,000. Institutional investors own 90.69% of the company’s stock.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 13,669 shares of the company’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $4.75, for a total value of $64,927.75. Following the sale, the insider owned 604,700 shares in the company, valued at approximately $2,872,325. The trade was a 2.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Rui Avelar sold 29,996 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $146,680.44. Following the completion of the sale, the insider directly owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. The trade was a 6.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 163,504 shares of company stock worth $797,184 in the last quarter. Corporate insiders own 6.10% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.